CONMED (CNMD) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.04
- Estimate
- $1.00
- Surprise
- +3.7%
- Revenue (period 2026-09-30)
- $335.6M
- Score at report (before → after)
- 5.3 → 5.3/10
Revenue source: xbrl.
How the report landed
CONMED (CNMD) beat the $1.00 estimate with adjusted EPS of $1.04 — a clear 3.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Sell at 5.3/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CNMD Sell at 5.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +3.7% surprise compares with a +11.2% four-quarter average. Next scheduled report: 2027-01-27.
What supports the rating
- Strong earnings beat streak (4/4)
- Attractive valuation
What argues against it
- Analyst target reached - limited upside remaining
- Weak overall score: 5.0/10
- Weak growth
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $47.90
- Stop
- $44.55
The stock trades at 20.1× trailing but 10.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
CNMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.44B
- P/E (fwd)
- 10.2
- P/E (ttm)
- 20.1
- 52-week range
- $31.44–$54.80
- Off 52-week high
- 12.6%
- RSI (14)
- 56
- Volume vs avg
- 0.47×
- Score today
- 5.0/10